FTC Pushes Congress To Pass Drug Settlement Bill

Law360, New York (June 1, 2009, 12:00 AM EDT) -- A top Federal Trade Commission official on Wednesday urged lawmakers to pass legislation banning so-called reverse payment patent settlements between brand-name pharmaceutical companies and their generic competitors.

The FTC's Bureau of Competition Director Richard A. Feinstein told a House Judiciary Committee hearing that the settlements now common in U.S. drug industry patent disputes are anti-competitive, and block rapid consumer access to lower-cost generics.

The settlements also impose additional costs on the country's health care system, Feinstein argued.

The FTC strongly backs H.R. 1706, the Protecting Consumer...
To view the full article, register now.